Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.98
Humacyte, Inc. incurred term loan of $77,500,000 with Avenue Venture Opportunities Fund II, L.P. at greater of (i) 11.50% and (ii) the sum of the Wall Street Journal Prime Rate plu maturing December 1, 2029.
- Instrument
- term loan
- Principal
- $77,500,000
- Counterparty
- Avenue Venture Opportunities Fund II, L.P.
- Rate
- greater of (i) 11.50% and (ii) the sum of the Wall Street Journal Prime Rate plu
- Maturity
- December 1, 2029
- Event
- incurrence
Exact text from the filing
On December 15, 2025 (the "Closing Date"), Humacyte, Inc. (the "Company") and Humacyte Global, Inc. ("Global", and together with the Company, the "Borrowers"), a wholly-owned subsidiary of the Company, entered into a loan and security agreement (the "Loan Agreement") with Avenue Venture Opportunities Fund II, L.P., as administrative agent and collateral agent for the lenders (the "Loan Agent") and as lender ("Avenue"), which provides for a senior secured term loan facility of up to $77,500,000 in the aggregate that matures on December 1, 2029, consisting of (i) an initial term loan of $40 million (the "First Tranche Term Loan"), which was fully funded on the Closing Date, (ii) a $12.5 million delayed draw term loan (the "Second Tranche Term Loan") which will be made available between October 1, 2026 and March 31, 2027, subject to the satisfaction of certain revenue, regulatory approvals and liquidity conditions, and (iii) a $25 million delayed draw term loan (the "Third Tranche Term Lo
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
Humacyte, Inc. issued up to a number of shares of Common Stock, equal to the quotient of (i) up to $5,037,500... and (ii) the applicable Warrant Price of warrant to Avenue Venture Opportunities Fund II, L.P..
- Security
- warrant
- Shares
- up to a number of shares of Common Stock, equal to the quotient of (i) up to $5,037,500... and (ii) the applicable Warrant Price
- Purchaser
- Avenue Venture Opportunities Fund II, L.P.
Exact text from the filing
On December 15, 2025, in connection with the Loan Agreement, the Company agreed to issue to Avenue a warrant (the “Warrant”) exercisable for up to a number of shares of Common Stock, equal to the quotient of (i) up to $5,037,500, consisting of (x) $3,412,500 and (y) upon the occurrence of the funding date of the Third Tranche Term Loan, $1,625,000, and (ii) the applicable Warrant Price
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Humacyte, Inc. entered into Loan Agreement with Avenue Venture Opportunities Fund II, L.P. valued at up to $77,500,000 (effective 2025-12-15).
- Action
- entry
- Agreement
- credit facility
- Counterparty
- Avenue Venture Opportunities Fund II, L.P.
- Value
- up to $77,500,000
- Effective
- 2025-12-15
Exact text from the filing
On December 15, 2025 (the “Closing Date”), Humacyte, Inc. (the “Company”) and Humacyte Global, Inc. (“Global”, and together with the Company, the “Borrowers”), a wholly-owned subsidiary of the Company, entered into a loan and security agreement (the “Loan Agreement”) with Avenue Venture Opportunities Fund II, L.P., as administrative agent and collateral agent for the lenders (the “Loan Agent”) and as lender (“Avenue”), which provides for a senior secured term loan facility of up to $77,500,000 in the aggregate
View on SEC.gov